- Conditions
- High Grade Gliomas, Brain Tumors
- Interventions
- adjuvant therapy, Temozolomide, Valproic Acid, Radiation therapy
- Procedure · Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 3
- States / cities
- Bethesda, Maryland • Philadelphia, Pennsylvania • Richmond, Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2305–2328
of 83,934
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Obesity
- Interventions
- Behavioral Intervention
- Behavioral
- Lead sponsor
- Geisinger Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Danville, Pennsylvania
- Conditions
- Esophagogastric Adenocarcinoma
- Interventions
- Nintedanib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 6
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
- Conditions
- Metastatic Anaplastic Thyroid Cancer
- Interventions
- durvalumab, tremelimumab, Stereotactic Body Radiotherapy (SBRT)
- Drug · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 8
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
- Conditions
- Alzheimers Disease
- Interventions
- Semaglutide, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 55 Years to 75 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Sun City, Arizona • Delray Beach, Florida
- Conditions
- Meibomian Gland Dysfunction, Dry Eye
- Interventions
- LipiFlow, Light Based (Sham) Treatment
- Device
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Bloomington, Indiana
- Conditions
- Anaemia
- Interventions
- GSK1278863 25 mg Tablet, Pioglitazone 15 mg Tablet, Rosuvastatin 10 mg Tablet, Trimethoprim 100 mg Tablet
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- BRAFV600E Melanoma Patients
- Interventions
- Dabrafenib, Gamma Knife Radiosurgery, Trametinib
- Drug · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Blepharospasm
- Interventions
- No intervention- only one time survey
- Other
- Lead sponsor
- Merz Pharmaceuticals GmbH
- Industry
- Eligibility
- 18 Years to 81 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 5
- States / cities
- Fountain Valley, California • Sarasota, Florida • Boston, Massachusetts + 2 more
- Conditions
- Healthy
- Interventions
- Canagliflozin, 100 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 50 mg/1000 mg, CANA/MET XR FDC, Formulation 2, 50 mg/1000 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Rheumatoid Arthritis, Cannabis
- Interventions
- 200mg Cannabidiol by capsules twice daily, 400mg Cannabidiol by capsules twice daily, Placebo capsules
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Semaglutide, Placebo (semaglutide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 72
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Coronado, California + 54 more
- Conditions
- Eating Disorders (Excluding Anorexia Nervosa), Depression
- Interventions
- High Intensity Strategy: Train-the-trainer, Low Intensity Strategy: Expert Consultation
- Behavioral
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Cerebrospinal Fluid Leak
- Interventions
- FS VH S/D 500 s-apr, DuraSeal Dural Sealant
- Drug · Device
- Lead sponsor
- Baxter Healthcare Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 10
- States / cities
- Springfield, Illinois • Springfield, Massachusetts • Detroit, Michigan + 7 more
- Conditions
- Skin Laxity
- Interventions
- Ulthera Treatment
- Device
- Lead sponsor
- Ulthera, Inc
- Industry
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Pasadena, California
- Conditions
- Sunscreening Agents
- Interventions
- Sunscreen Lotion (BAY987521), Untreated Skin
- Other
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Piscataway, New Jersey
- Conditions
- Vitreomacular Adhesion Including Macular Hole
- Interventions
- Ocriplasmin, Sham injection
- Drug · Other
- Lead sponsor
- ThromboGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 22 more
- Conditions
- Cardiac Arrest
- Interventions
- Standard Care, Low Volume Hemofiltration, High Volume Hemofiltration
- Other · Device
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- Ofatumumab, Rituximab
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 438 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 70
- States / cities
- Anchorage, Alaska • Gilbert, Arizona • Hot Springs, Arkansas + 63 more
- Conditions
- Solid Tumor, Advanced Solid Tumor
- Interventions
- M4344 10 mg BIW, M4344 20 mg BIW, M4344 40 mg BIW, M4344 80 mg BIW, M4344 160 mg BIW, M4344 300 mg BIW, M4344 450 mg BIW, M4344 700 mg BIW, M4344 1050 mg BIW, M4344 1200 mg BIW, M4344 100 mg BID, M4344 150 mg QD, M4344 250 mg QD, M4344 350 mg QD, M4344 400 mg, M4344 500 mg, Carboplatin
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 8
- States / cities
- Boston, Massachusetts • Ann Arbor, Michigan • St Louis, Missouri + 4 more
- Conditions
- CD 19+ Acute Leukemia
- Interventions
- T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)
- Biological
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2033
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Graft vs. Host Disease
- Interventions
- Brentuximab Vedotin
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • New York, New York • Columbus, Ohio
- Conditions
- Infertility
- Interventions
- SMART System, Culture dish
- Device
- Lead sponsor
- Incept BioSystems, Inc.
- Industry
- Eligibility
- 21 Years to 35 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 4
- States / cities
- San Francisco, California • Clearwater, Florida • Mt. Pleasant, South Carolina + 1 more
- Conditions
- Obesity
- Interventions
- Nimacimab injection, Nimacimab placebo injection, semaglutide injection, Nimacimab 300 mg injection
- Biological · Combination Product
- Lead sponsor
- Skye Bioscience, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 16
- States / cities
- Anniston, Alabama • Walnut Creek, California • Waterbury, Connecticut + 13 more